Capsida Biotherapeutics
Cell & Gene Therapy · Biotechnology
Clinical trials: 3No open roles listed
Data updated Nov 21, 2026Full reportReport a mistake
Lately:1 news story in 90 daysFollow changes →
Facts
as of Nov 21, 2026Capsida Biotherapeutics is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening disorders.
- Founded
- 2019
- Official records
- Wikidata Q119857248
- Website
- capsida.com
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
Products
Products →Capsida Biotherapeutics has 3 clinical trials on record, 0 under way.
Clinical trials
A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease
phase 2 · stopped or withdrawn · GBA1 Parkinson Disease
Aug 2025
A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy
phase 2 · stopped or withdrawn · 1 participants · Developmental and Epileptic Encephalopathy
Jul 2025
Natural History Study in Pediatric Patients with STXBP1 Encephalopathy with Epilepsy
stopped or withdrawn · STXBP1 Encephalopathy with Epilepsy
Oct 2024
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.
Risk
Full record →Capsida Biotherapeutics: 9 research papers in five years.
No match
None
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Milestones
Founded
2019
Newsroom
NewsPharmaceutical Executive
Oct 8
Sources: the outlets named on each headline, each story once
